´╗┐Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is key

Ann Rheum Dis. 2019 Jan;78(1):141-142. doi: 10.1136/annrheumdis-2018-213547. Epub 2018 Aug 27.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Antirheumatic Agents / administration & dosage
  • Antirheumatic Agents / economics*
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / economics*
  • Clinical Protocols*
  • Cost-Benefit Analysis
  • Deprescriptions*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Quality-Adjusted Life Years
  • Randomized Controlled Trials as Topic

Substances

  • Antirheumatic Agents